Opiant Pharmaceuticals (NASDAQ:OPNT)‘s stock had its “buy” rating reaffirmed by stock analysts at Northland Securities in a research note issued on Thursday, AnalystRatings.com reports. They currently have a $42.00 target price on the technology company’s stock. Northland Securities’ price target indicates a potential upside of 165.82% from the company’s previous close.
Separately, TheStreet upgraded Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a research report on Friday, August 30th.
OPNT traded up $0.38 during trading on Thursday, reaching $15.80. 6,400 shares of the company’s stock were exchanged, compared to its average volume of 20,137. The company has a market capitalization of $61.02 million, a P/E ratio of -2.23 and a beta of 0.31. Opiant Pharmaceuticals has a fifty-two week low of $9.98 and a fifty-two week high of $17.02. The business has a 50 day moving average price of $15.06 and a 200 day moving average price of $13.47.
In related news, insider Phil Skolnick sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $14.68, for a total value of $146,800.00. Also, Director Michael Sinclair sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $12.52, for a total value of $751,200.00. Insiders sold a total of 90,000 shares of company stock valued at $1,197,500 over the last quarter. 30.88% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Wedge Capital Management L L P NC acquired a new position in shares of Opiant Pharmaceuticals in the 3rd quarter valued at approximately $363,000. Morgan Stanley grew its position in shares of Opiant Pharmaceuticals by 1,000.3% in the 2nd quarter. Morgan Stanley now owns 22,414 shares of the technology company’s stock valued at $297,000 after purchasing an additional 20,377 shares during the period. Stonepine Capital Management LLC grew its position in shares of Opiant Pharmaceuticals by 7.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 315,468 shares of the technology company’s stock valued at $4,180,000 after purchasing an additional 20,574 shares during the period. BlackRock Inc. lifted its stake in Opiant Pharmaceuticals by 93.5% in the 2nd quarter. BlackRock Inc. now owns 20,792 shares of the technology company’s stock valued at $276,000 after acquiring an additional 10,045 shares in the last quarter. Finally, Advisor Group Inc. lifted its stake in Opiant Pharmaceuticals by 24.3% in the 2nd quarter. Advisor Group Inc. now owns 4,600 shares of the technology company’s stock valued at $61,000 after acquiring an additional 900 shares in the last quarter. Institutional investors and hedge funds own 20.82% of the company’s stock.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
See Also: What is Cost of Debt?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.